Pfizer sees no antitrust hurdles from buying AstraZeneca
LONDON May 13 (Reuters) - Pfizer Chief Executive Ian Read said on Tuesday he did not believe there would be antitrust problems in taking over British drugmaker AstraZeneca .
"We don't see any substantial antitrust issues on this deal anywhere in the world," Read told a panel of British lawmakers.
The U.S. drugmaker has fuelled a major political row with its $106 billion plan to acquire AstraZeneca, which has been rebuffed by the smaller British company.
The deal would be the largest foreign takeover of a British firm and is opposed by many scientists, trade unions and politicians who fear for British science jobs given Pfizer's track record of cost cutting after past acquisitions.
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- Secret Service investigates after man jumps White House fence, reaches doors
- About 60,000 Syrian Kurds flee to Turkey from Islamic State advance |
- U.S. immigration protesters drop U.S. border blockade plan
- French jets strike in Iraq, expanding U.S.-led campaign against Islamic State |